Functional and Applied Genomics Laboratory, National Center of Excellence in Molecular Biology, University of Punjab, Lahore, Pakistan.
Liver Int. 2011 May;31(5):606-17. doi: 10.1111/j.1478-3231.2010.02442.x. Epub 2011 Jan 24.
p7, a 63-residue peptide encoded by hepatitis C virus (HCV), a major pathogen associated with a risk of developing severe liver disease, is involved in ion channel activity in lipid bilayer membranes both in in vitro and cell-based assays. p7 protein consists of two transmembrane α-helices, TM1 and TM2 connected by a loop oriented towards the cytoplasm. HCV relies on p7 function in addition to ion channel formation for efficient assembly, release and production of infectious progeny virions from liver cells. p7 activity is strictly sequence specific as mutation analysis showed the loss of ion channel function. Moreover, p7 ion channel activity can be specifically inhibited by different drugs suggesting the protein as a new target for future antiviral chemotherapy. In the present review, we focused to bring together the recent development to explore the potential role of p7 protein in HCV infection and its inhibition as a therapy.
p7 是丙型肝炎病毒(HCV)编码的一种 63 个残基的肽,是与严重肝脏疾病风险相关的主要病原体之一,它参与了体外和基于细胞的测定中脂质双层膜中的离子通道活性。p7 蛋白由两个跨膜 α-螺旋 TM1 和 TM2 组成,由一个朝向细胞质的环连接。除了形成离子通道外,HCV 还依赖于 p7 的功能,以有效地从肝细胞中组装、释放和产生感染性子代病毒颗粒。p7 的活性是严格的序列特异性的,因为突变分析表明其丧失了离子通道功能。此外,p7 离子通道的活性可以被不同的药物特异性抑制,这表明该蛋白是未来抗病毒化疗的一个新靶点。在本综述中,我们重点介绍了最近的研究进展,以探讨 p7 蛋白在 HCV 感染及其抑制作为治疗中的潜在作用。